Syndicate this blog

Archives

Posted 2006-11-24 12:51:06

EDMONTON, Canada | Nov 23, 2006 | BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the first patients have been enrolled in its placebo controlled multi-center Phase II clinical trial of MBP8298 for the treatment of relapsing remitting multiple sclerosis (RRMS).

Share this link?   Digg   Reddit   Del.icio.us